Pericarditis

benefit from a trial of pharmacotherapy first, rather than pericardiectomy. Measures that minimize the risk of developing constrictive pericarditis include the following (5): Timely guideline-based treatment of acute and recurrent pericarditis Complete drainage of infected pericardial effusions In patients undergoing pericardiotomy, prophylactic colchicine and drainage of postpericardiotomy pericardial effusions Treatment references 1. Adler Y, Charron P, Imazio M, et al: 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio- Thoracic Surgery (EACTS). Eur Heart J 36(42):2921–2964, 2015. doi:10.1093/eurheartj/ehv318 2. Imazio M, Brucato A, Cemin R, et al: A randomized trial of colchicine for acute pericarditis. N Engl J Med 369(16):1522–1528, 2013. doi:10.1056/NEJMoa1208536 3. Abadie BQ, Cremer PC: Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis. BioDrugs 36(4):459–472, 2022. doi:10.1007/s40259-022-00537-7 4. Hoit BD: Pericardial Effusion and Cardiac Tamponade Pathophysiology and New Approaches to Treatment. Curr Cardiol Rep 25(9):1003–1014, 2023. doi:10.1007/s11886-023-01920-8 5. Lazaros G, Vlachopoulos C, Lazarou E, Tsioufis K: New Approaches to Management of Pericardial Effusions. Curr Cardiol Rep 23(8):106, 2021. Published 2021 Jul 1. doi:10.1007/s11886-021-01539-7 Key Points Patients with pericarditis may have symptoms
